凝固因子XIIのハプロイン欠乏症は,集団規模の多次元分析で静脈性血栓塞栓症に対して保護的である
Amelia K Haj1,2,3, David S Paul4,5, Sean J Jurgens2,6,7
1Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Nature communications
|September 1, 2025
まとめ
血液凝固因子XII (F12) の遺伝的変異は,出血リスクを増加させずに静脈血栓栓症を予防します. これは,ファクターXIIの抑制が安全で効果的な治療法であることを示唆しています.
科学分野:
- 遺伝学
- ヘモスタシス
- 薬理学について
背景:
- 凝固因子XII (F12) は,血栓形成を予防する潜在的薬剤標的である.
- F12を標的とする治療法を支持するヒトのデータは限られている.
- 静脈血栓塞栓症 (VTE) に関するF12の役割の調査は極めて重要です.
研究 の 目的:
- 人間の遺伝データを用いて,静脈血栓塞栓症におけるF12の役割を評価する.
- 血液と感染に関するF12変異の安全性プロフィールを評価する.
- 血栓形成におけるF12欠乏のメカニズムを調査する.
主な方法:
- 英国バイオバンクとNIH All of Usの70万3745人の参加者におけるF12の遺伝子変異の分析.
- 出血,感染,およびF12レベルを含むF12変異媒体の表型特性.
- インビトロトロンビン生成アッセイ
- VTEの保護のためのF12ヘテロジゴットマウスモデルの評価.
主要な成果:
- F12変種 (無意味,フレームシフト,スプライスサイト) のヘテロジゴトのキャリアは,VTEに対する保護を示した.
- F12変異のキャリアでは,出血や感染のリスクは増加しなかった.
- F12変異のキャリアは量的な (タイプI) F12欠乏を示し,一部は質的な (タイプII) 欠乏を示した.
- キャリアにおけるF12濃度と相関する in vitro トロンビン生成の減少
- F12の異卵性マウスはVTEから保護された.
結論:
- F12機能のヘテロジゴスな喪失は,VTEに対する保護を与える.
- このハプロインサフィエンス状態は,F12抑制が潜在的に安全で効果的な治療方法であることを示唆しています.
- F12を標的にすることは,血栓の予防のためにさらなる調査を正当化します.
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K